Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > HCM Hutchmed (China) > Detailed Quotes

HCM Hutchmed (China)

9.300
+0.070+0.76%
Close 10/05 16:00 ET
9.3000.0000.00%
Post Mkt Price 10/05 16:01 ET
High
9.370
Open
9.330
Turnover
1.81M
Low
9.040
Pre Close
9.230
Volume
195.69K
Market Cap
1.61B
P/E(TTM)
Loss
52wk High
36.370
Shares
172.96M
P/E(Static)
Loss
52wk Low
8.370
Float Cap
855.05M
Bid/Ask %
-96.72%
Historical High
43.940
Shs Float
91.94M
Volume Ratio
0.75
Historical Low
8.370
Dividend TTM
--
Div Yield TTM
--
P/B
2.01
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.21%
Amplitude
3.58%
Avg Price
9.240
Lot Size
1
Float Cap
855.05M
Bid/Ask %
-96.72%
Historical High
43.940
Shs Float
91.94M
Volume Ratio
0.75
Historical Low
8.370
Dividend TTM
--
P/B
2.01
Dividend LFY
--
Turnover Ratio
0.21%
Amplitude
3.58%
Avg Price
9.240
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
HUTCHMED (China) Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for cancer and immunological diseases in the People’s Republic of China and Hong Kong. The company provides research and development services; and develops, manufactures, distributes, markets, and sells prescription pharmaceutical products Its clinical stage drugs include Savolitinib, a MET inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. Surufatinib, an inhibitor for the treatment of neuroendocrine tumors and solid tumors; and HMPL-523 for the treatment of hematological cancer and immunological diseases; HMPL-689 for the treatment of hematological cancer; HMPL-453 for the treatment of solid tumors; and HMPL-306 for the treatment of hematological malignancies, gliomas, and solid tumors, as well as epitinib and theliatinib, an EGFR inhibitor to penetrate the blood-brain barrier. Hutchison China MediTech Limited was founded in 2000 and is headquartered in Hong Kong, China.
CEO: Dr. Weiguo Su
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...